RTP Mobile Logo
Lung Cancer Update, Issue 3, 2013
Released January 2014

Featuring interviews with Drs Thomas J Lynch Jr, Billy W Loo Jr, Nathan A Pennell, Karen L Reckamp and Vera Hirsh. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Lung cancer is the leading cause of cancer mortality in the United States for both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes. However, the advent of biologic agents in lung cancer has led to recent improvements in disease-free and overall survival in select patient populations. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists and radiation oncologists with the formulation of up-to-date clinical management strategies for the care of patients with lung cancer.

    LEARNING OBJECTIVES

    • Critically appraise the efficacy and safety of stereotactic ablative radiation therapy for the local treatment of early-stage NSCLC.
    • Apply the results of existing and emerging clinical research to the multimodality treatment of Stage III NSCLC.
    • Formulate a rational approach to identifying molecular determinates from tumor specimens that may be used to refine lung cancer prognosis and/or predict therapeutic response to an individual treatment.
    • Develop an evidence-based approach to the selection of induction and maintenance biologic therapy and/or chemotherapy for patients with advanced NSCLC.
    • Identify distinct subtypes of adenocarcinoma of the lung — including those with EGFR mutations, EML4-ALK gene fusions, ROS1 gene rearrangements and other recently identified driver mutations — and the approved and investigational treatment options for patients with these mutations.
    • Review emerging research evidence with the use of the irreversible EGFR tyrosine kinase inhibitor afatinib alone or in combination with an EGFR monoclonal antibody for patients with advanced EGFR mutation-positive NSCLC.
    • Recall the scientific rationale for ongoing investigation of novel agents or immunotherapeutic approaches in lung cancer, and counsel appropriately selected patients about study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr LynchAdvisory Committee and Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Merck; Board of Directors: Infinity Pharmaceuticals Inc; Other Remunerated Activities: Partners HealthCare. Dr LooResearch Support: RaySearch Laboratories, Varian Medical Systems Inc. Dr PennellConsulting Agreement: Genentech BioOncology. Dr ReckampAdvisory Committee: Boehringer Ingelheim Pharmaceuticals Inc; Consulting Agreement: Amgen Inc; Contracted Research: Astellas, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc. Dr HirshAdvisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Lilly, Pfizer Inc, Roche Laboratories Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This activity is supported by educational grants from Astellas, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Lilly and Novartis Pharmaceuticals Corporation.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    January 2014
    Expiration date: January 2015

Acknowledge and close

Listen to audio:
Lung Cancer Update, Issue 3, 2013
Released January 2014

Featuring interviews with Drs Thomas J Lynch Jr, Billy W Loo Jr, Nathan A Pennell, Karen L Reckamp and Vera Hirsh. (Text and Audio Content)

Read print: